(Q34180965)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

main subject

phase II clinical trial

0 references

peripheral neuropathy

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Miguel Martin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

4

Gabriel N Hortobagyi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

12

Edith A Perez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

5

Joseph A Sparano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Eva S Thomas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Henri H Roché

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Louise Yelle

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Monica N Fornier

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Craig A Bunnell

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Pralay Mukhopadhyay

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Ronald A Peck

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

2 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

Supportive Care in Cancer

24 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

2661-2668

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

24 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Proactive management of adverse events maintains the clinical benefit of ixabepilone

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Efficacy and safety of ixabepilone, a novel epothilone analogue.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Novel agents that target tublin and related elements

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Peripheral neuropathy induced by microtubule-stabilizing agents.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Approach to peripheral neuropathy and neuronopathy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Motor neuropathy due to docetaxel and paclitaxel

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Peripheral neuropathy secondary to docetaxel (Taxotere)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

5 July 2018

Neurotoxicity of Taxol.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Paclitaxel-induced neuropathy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Promotion of microtubule assembly in vitro by taxol

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461204

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

5 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1384-0

Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1384-0

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1384-0

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1384-0

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1384-0

Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes

21 January 2018

1 reference

12 December 2020

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy

1 reference

12 December 2020

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy

1 reference

12 December 2020

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

1 reference

12 December 2020

10.1007/S00520-012-1384-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

PubMed publication ID

22382588

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22382588%20AND%20SRC:MED&resulttype=core&format=json